Eflornithine
Eflornithine

49.3
Targets key enzymes in hair follicles to slow the growth of unwanted facial hair.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Eflornithine hydrochloride
Reference Brand
Vaniqa
Product Origin
Generic Product
Reference Manufacturer
Almirall
Product Form
Cream, Injectable Solution
Regulatory Classification
Rx
Primary Category
Women's Health, Skin Care
Product Category
Enzyme Inhibitor
Pharmacological Class
Ornithine Decarboxylase Inhibitor
Clinical Indications
Manufacturer Description
Utilized for facial hirsutism in women to manage unwanted hair growth and support skin appearance.
Mechanism of Action
Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme in the skin follicle required for hair growth. This slows the rate of hair growth, leading to thinner and less prominent facial hair over time.
Route of Administration
Topical
Onset Time
4–8 weeks
Duration
Ongoing use required
Contraindications
Hypersensitivity to eflornithine
Severe Adverse Events
Anaphylaxis, Angioedema, Severe contact dermatitis — requires immediate medical attention
Common Side Effects
Skin redness, Stinging, Burning
Uncommon Side Effects
Acne, Skin dryness, Folliculitis
Drug Interactions
Alcohol
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Compatible with caution.
Age Restrictions
Safety and efficacy established in pediatric patients 12 years and older.
Storage Guidelines
Store at room temperature; do not freeze.
Related Products
Vaniqa
Information related to Eflornithine is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
Where to buy Arthritis - Allopurinol Gout Tablet